ONGLYZA 5 MG Israel - English - Ministry of Health

onglyza 5 mg

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ONGLYZA 2.5 MG Israel - English - Ministry of Health

onglyza 2.5 mg

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

LAMISIL SPRAY Israel - English - Ministry of Health

lamisil spray

gsk consumer healthcare, israel ltd - terbinafine hydrochloride - solution - terbinafine hydrochloride 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum) , microsporum canis and epidermaphyton floccosum.yeast infections of the skin, principally those caused by the genus candida (e.g. candida albicans). pityriasis (tinea) versicolor due to pityrosporum orbiculare (also known as malassezia furfur).

SELGIN Israel - English - Ministry of Health

selgin

cts chemical industries ltd, israel - selegiline hydrochloride - tablets - selegiline hydrochloride 5 mg - selegiline - selegiline - treatment of parkinson's disease or symptomatic parkinsonism.

V-OPTIC 0.5% Israel - English - Ministry of Health

v-optic 0.5%

vitamed pharmaceutical industries ltd - timolol as maleate - drops - timolol as maleate 5 mg/ml - timolol - timolol - for the reduction of elevated intraocular pressure.may be used in patients with chronic open angle glaucoma, aphakic glaucoma, some patients with secondary glaucoma and patients with ocular hypertension.

V-OPTIC 0.25% Israel - English - Ministry of Health

v-optic 0.25%

vitamed pharmaceutical industries ltd - timolol as maleate - drops - timolol as maleate 2.5 mg/ml - timolol - timolol - for the reduction of elevated intraocular pressure.may be used in patients with chronic open angle glaucoma, aphakic glaucoma, some patients with secondary glaucoma and patients with ocular hypertension.

NORMALAX Israel - English - Ministry of Health

normalax

taro pharmaceutical industries ltd - polyethylene glycol 3350 - powder for solution - polyethylene glycol 3350 100 %w/w - osmotically acting laxatives - for the treatment of constipation.

IMPAVIDO 10 MG Israel - English - Ministry of Health

impavido 10 mg

megapharm ltd - miltefosine - hard capsule - miltefosine 10 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

IMPAVIDO 50 MG Israel - English - Ministry of Health

impavido 50 mg

megapharm ltd - miltefosine - hard capsule - miltefosine 50 mg - miltefosine - -treatment of visceral leishmaniasis caused by leishmania donovani. -treatment of cutaneous leishmaniasis caused by leishmania brasiliensis complex or leishmania mexicana complex.

STRATTERA 4 MGML ORAL SOLUTION Israel - English - Ministry of Health

strattera 4 mgml oral solution

eli lilly israel ltd, israel - atomoxetine - solution (oral) - atomoxetine 4 mg / 1 ml - atomoxetine - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd.in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and strattera should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd. based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.